Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Glutathione iconGlutathione3 residuesECGEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Glutathione

Beginner tier: 200 mg, 2x/week · 12w on / 2w off · community consensus

Anti-AgingCompounded
10 min half-life·Injection

Also known as: GSH, L-Glutathione, Reduced Glutathione

Three amino acids. That is all glutathione is. Glutamate, cysteine, and glycine form a tripeptide that every cell in the body produces, and every cell depends on. Oral supplements barely register in bloodwork because proteases destroy roughly 90% of ingested GSH before it reaches circulation. Injectable glutathione bypasses that bottleneck entirely, delivering 100% bioavailability through subcutaneous, intramuscular, or IV routes. The skin brightening data is thin. One placebo-controlled RCT saw 37.5% respond after 12 sessions versus 18.7% on placebo, short of statistical significance. Effects faded within six months of stopping. Athletes, longevity enthusiasts, and skin-focused users make up the core community, typically running 200 to 400 mg subcutaneous two to three times per week.

What Is Glutathione?

Every cell in the body produces glutathione, and every cell runs out of it under stress. GSH (L-glutathione, gamma-glutamylcysteinylglycine, CAS 70-18-8) is a tripeptide antioxidant that donates electrons to neutralize reactive oxygen species, then gets recycled by glutathione reductase using NADPH. That recycling loop is the reason it earned the "master antioxidant" label in biochemistry textbooks.

Oral glutathione supplements have a bioavailability problem. GI proteases break down roughly 90% before absorption. A 2015 randomized controlled trial (Richie et al., n=54)[1] showed that 1,000 mg/day oral GSH raised body stores modestly over six months. Liposomal formulations do somewhat better (2019)[2]. But parenteral routes bypass digestion entirely and deliver near-100% bioavailability.

Injectable GSH is used for three main goals: general antioxidant and detoxification support, exercise recovery, and skin brightening. The skin brightening pathway is specific; GSH inhibits tyrosinase and shifts melanin production from dark eumelanin toward lighter phaeomelanin. Zubair and colleagues tested this in a 2016 placebo-controlled trial (J Pak Assoc Dermatol) using 1,200 mg IV glutathione with vitamin C twice per week for 12 sessions. Response rate was 37.5% in the treatment group versus 18.7% placebo (p=0.054, not statistically significant;)[3]. The effect was not permanent; at the six-month follow-up only one patient kept the improvement.

No FDA-approved injectable glutathione product exists. All parenteral GSH comes from 503A or 503B compounding pharmacies, and sourcing quality matters. The FDA documented seven endotoxin poisoning hospitalizations from contaminated compounded glutathione in 2019. Community protocols for home use run 200 to 400 mg subcutaneous, two to three times per week, at a fraction of the risk profile that IV protocols carry.

How Glutathione Works

Glutathione is a tripeptide of glutamate, cysteine, and glycine. The cysteine residue carries a sulfhydryl group that donates electrons directly to reactive oxygen species and free radicals. When GSH donates an electron, it becomes oxidized glutathione (GSSG). The enzyme glutathione reductase then regenerates GSH from GSSG, burning NADPH in the process. This redox cycle runs continuously in every cell.

GSH also works as a cofactor. Glutathione peroxidase uses it to reduce hydrogen peroxide and lipid hydroperoxides. Glutathione S-transferase uses it in Phase II liver detoxification, conjugating xenobiotics and drug metabolites for excretion. These pathways handle acetaminophen metabolism, environmental toxin clearance, and heavy metal chelation.

The skin brightening mechanism is distinct from general antioxidant activity. In melanocytes, GSH inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis. It also shifts the melanogenesis pathway from eumelanin (dark pigment) toward phaeomelanin (lighter pigment). Watanabe and colleagues described this mechanism in a 2017 review [4]. The clinical result, when it occurs, is gradual skin lightening and tone evening.

Plasma half-life of IV glutathione is roughly 10 minutes (Aebi et al., 1991)[5]. That sounds short, but intracellular GSH pools turn over on a two to three hour cycle. Parenteral delivery floods cells with substrate that sustains intracellular levels well beyond the plasma clearance window.

Glutathione Benefits

  • Glutathione benefits center on antioxidant protection, detoxification, and skin brightening.
  • Near-complete bioavailability through injection; parenteral routes deliver close to 100% versus roughly 10% from oral supplements (Richie et al. 2015,confirmed the oral absorption gap in 54 subjects)[1].
  • Skin brightening in responders after 12 sessions. The Zubair 2016 placebo-controlled trial measured a 37.5% response rate with 1,200 mg IV twice weekly, versus 18.7% on placebo (p=0.054;)[3]. Non-responders made up the majority, so expectations should be realistic.
  • Faster exercise recovery and reduced post-workout soreness. Community reports across 50 to 150+ Reddit threads consistently describe this benefit within the first two weeks of subcutaneous dosing.
  • Phase II liver detoxification support. GSH conjugation is the primary clearance pathway for acetaminophen metabolites and environmental toxins. Clinicians use IV GSH in acetaminophen overdose protocols alongside N-acetylcysteine.
  • Reduced brain fog and improved energy. Users on r/Peptides and r/Nootropics report cognitive clarity gains within the first few sessions, especially with IV administration.
  • Zinc preservation is the trade-off at high doses. Chronic use above 600 mg three times per week may deplete zinc stores, so monitoring serum zinc at 8 to 12 weeks is advisable.

Glutathione: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 12 key studies·Compounded

Antioxidant biochemistry is well-established; skin brightening has one placebo-controlled IV RCT showing ~37.5% response with results fading at 6 months; 2024–2025 systematic reviews conclude IV route risks outweigh any brightening benefit.

Dosing studied: 200–600 mg SubQ/IM for antioxidant use; 1,200 mg IV 2×/week used in published skin-brightening RCT; Parkinson's adjunct trials used 1,400–2,800 mg IV 3×/week
Read the evidence (key study, limitations)
Key Study

Zubair et al. 2016 (J Pak Assoc Dermatol, not PubMed-indexed): 1,200 mg IV glutathione plus vitamin C 2×/week × 12 sessions; 37.5% response vs. 18.7% placebo (p=0.054); only 1 patient kept the effect at 6-month follow-up; 8 stopped for deranged liver function tests and 1 for anaphylaxis

Limitations

Only one placebo-controlled IV skin-brightening RCT; 2024 systematic review (PMID 39444151) concluded "IV glutathione is contraindicated due to lack of efficacy and side effects"; no head-to-head SubQ vs. IV comparison; no RCT for antioxidant/energy indications; Parkinson's IV RCT (PMID 19230029, n=20) showed no significant UPDRS difference vs. placebo (P=0.32)

Community Experience
Strong
3.8/5
Based on ~50–150+ threads across r/Peptides, r/Nootropics, r/SkincareAddiction

Widely used for energy, recovery, and skin brightening.

Community dosing: 200–400 mg SubQ/IM 2–3×/week (home); 600–1,200 mg IV 1–2×/week (clinic); skin brightening protocols often 600 mg IM 3×/week
Read the reports (what users report 5, common issues 5)

Home SubQ at 200–400 mg 2–3×/week is the dominant protocol. Skin brightening outcomes described as inconsistent.

What users report (5)
  • Increased energy and reduced brain fog (reported within 1–2 weeks)
  • Faster exercise recovery and reduced muscle soreness
  • Skin brightening and tone evening in responders after 6–12 sessions
  • Reduced hangover severity
  • Improved mood and sleep quality
Common issues (5)
  • Skin brightening inconsistent: approximately 37% respond; effects fade after stopping
  • IV administration requires clinic visit and carries higher risk
  • Endotoxin contamination risk from non-pharmaceutical-grade compounded product
  • Injection site reactions with repeated SubQ dosing at same sites
  • Sulfite sensitivity reactions reported in susceptible individuals
Partially Aligned

Community uses GSH broadly for energy, recovery, and skin goals; science validates antioxidant biochemistry but skin brightening evidence is limited (one RCT, 37.5% response, non-permanent). Recent 2024–2025 clinical reviews increasingly caution against IV route while community continues to use it. Community dosing (200–600 mg SubQ) is lower than clinical trial doses (1,200 mg IV) creating a protocol gap.

Glutathione Dosage Guide

CommunityCompounded glutathione: community dosing consensus
LevelDose / InjectionFrequency
Beginner200 mg
2x/weekTrack
Moderate400 mg
2x/weekTrack
Aggressive600 mg
3x/weekTrack
Note:

A standard compounded vial is 1,500 mg. Add 3 mL bacteriostatic water and you get a concentration of 500 mg/mL. At that concentration, a 200 mg dose is 0.4 mL, which is 40 units on a U-100 insulin syringe. A 400 mg dose is 80 units. A 600 mg dose is 120 units, which exceeds a standard 1 mL syringe; split it into two 60-unit injections or use a 3 mL syringe with a 27G needle.

GSH is light-sensitive. Store vials away from direct light, refrigerated at 2 to 8 degrees Celsius. Reconstituted vials stay good for about four weeks.

The thing most beginners miss: oral NAC (N-acetylcysteine) between injection days supports endogenous GSH synthesis and is significantly cheaper. Stacking 600 to 1,200 mg oral NAC on off-days extends the benefit of your injection protocol without adding injection frequency. Vitamin C (1 to 2 g oral) directly regenerates oxidized GSSG back to reduced GSH through the ascorbate-glutathione redox cycle.

Cycling Protocol

On Period
12 weeks
Off Period
2 weeks

No desensitization documented, but periodic breaks are commonly recommended. Some users maintain indefinitely at lower frequency (1x/week) without cycling off.

Calculate your Glutathione dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Glutathione Protocols by Goal

beginnerCommunity8-week loading, then ongoing maintenance
Loading
Wk 1–8
200 mg · 2–3×/week · SubQ
Maintenance
Wk 9+
200 mg · 1×/week · SubQ

Expected: Improved energy, reduced brain fog, enhanced exercise recovery; effects sustained with maintenance dosing

Monitor: No blood work required at beginner doses. Monitor for injection site reactions and systemic allergic symptoms.

How to Use Glutathione

  1. 1
    Wash hands thoroughly

    Clean the vial stopper and injection site with alcohol swabs. Let both air-dry for 10 seconds.

  2. 2
    Step 2

    Draw 3 mL of bacteriostatic water into a syringe and inject it slowly into the 1,500 mg glutathione vial. Direct the stream against the glass wall, not the powder. Swirl gently until dissolved. Do not shake.

  3. 3
    Step 3

    Using a U-100 insulin syringe (29 to 31 gauge, 0.5 inch needle), draw your dose: 40 units for 200 mg, 80 units for 400 mg, or split 600 mg into two 60-unit draws.

  4. 4
    Pinch a fold of abdominal fat or upper thigh

    Insert the needle at a 45 to 90 degree angle depending on body composition. Inject slowly over 30 to 60 seconds. Slower injection reduces discomfort.

  5. 5
    Step 5

    Withdraw the needle and apply light pressure with a cotton ball. Do not rub.

  6. 6
    Step 6

    Rotate injection sites each dose, maintaining at least 2 to 3 cm from your previous site to prevent lipohypertrophy.

  7. 7
    Step 7

    Return the vial to the refrigerator (2 to 8 degrees Celsius) immediately. Protect from light. Discard after four weeks from reconstitution.

  8. 8
    Timing is flexible

    Post-workout or morning dosing is common, but GSH has no meal timing dependency. Stacking with 1 to 2 g oral vitamin C on injection days supports the redox recycling pathway.

Alternative Routes

Subcutaneous (SubQ)

Same mg dose as IM; Tmax ~30–60 min vs. 15–30 min IM

Use 27–31G insulin syringe. Inject into abdominal fat or upper thigh over 30–60 seconds to minimize discomfort. Rotate sites. Most practical and cost-effective home route.

Intramuscular (IM)

Equivalent mg dose; faster absorption. Volumes >1 mL more comfortable via IM vs. SubQ.

Deltoid or ventrogluteal preferred. Used clinically for 200–600 mg doses. Larger-volume injections (1.2 mL at 600 mg with 500 mg/mL vial) better tolerated IM.

Intravenous (IV)

Immediate peak plasma concentration; doses 600–1,200 mg used vs. 200–600 mg SubQ/IM

Slow infusion over 15–30 minutes minimum: never rapid push. Rate-dependent side effects (flushing, nausea, chest tightness) resolve by slowing infusion. Anaphylaxis management must be immediately available.

Oral (standard)

~10× dose required for equivalent plasma effect; liposomal oral formulations modestly improve bioavailability

PMID 28853742 (2019) shows liposomal oral GSH increases whole blood glutathione vs. placebo, but does not match parenteral routes for acute elevation. Oral NAC (N-acetylcysteine) is a practical precursor bridge between injection sessions.

Intranasal

Not established for home protocols; device-assisted delivery required

IV PD protocol (1,400–2,800 mg 3×/week) failed primary endpoint in one RCT (PMID 19230029, n=20, P=0.32). Intranasal delivery is under investigation as a CNS-targeted alternative. No home protocol exists.

Mixing your own vial? Use the Glutathione reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

Glutathione Stacking Protocols

Works With

Avoid

Ozone therapy (IV ozone)

IV glutathione directly neutralizes ozone through free radical scavenging; concurrent or same-session administration creates potentially harmful oxidative byproducts and defeats the therapeutic purpose of both treatments. PMID 40408806 (2025) explicitly warns against this combination.

Do not combine
Nitroglycerin

Glutathione potentiates hypotensive effects of nitroglycerin. Concurrent use may produce clinically significant blood pressure drop.

How much does Glutathione cost?

Typical price

$0.036 to $0.0594 per mg

Typical $0.0467

Middle half of 61 US prices for 1500 mg vials · read Oct 31

See prices

Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.

Compounded
~$50–$120 per 600 mg vial; ~$150–$200 per 1,200 mg vial (503A pharmacy, Rx required); clinic IV session $150–$500+ depending on location (metropolitan clinics LA/NYC $250–$500+); telehealth subscription plans ~$95–$149/month
Brand Price
No standalone injectable brand pharmaceutical available in the US; Setria (Kyowa Hakko) is a branded ingredient in oral supplements only: not an injectable product

Pricing updated 2026-04-09

Glutathione Side Effects

The most serious documented risk with injectable glutathione is endotoxin contamination from poorly compounded product. The FDA issued a 2019 safety alert after seven people were hospitalized with endotoxin poisoning from contaminated compounded glutathione traced to bulk glutathione powder from one company, distributed to approximately 100 compounders across 30 states. Symptoms included fever, chills, hypotension, and tachycardia consistent with systemic inflammatory response syndrome (SIRS). This is a sourcing risk, not an inherent pharmacological risk, but it is the single most dangerous thing that can go wrong.

Anaphylaxis is documented. The Zubair 2016 placebo-controlled trial (J Pak Assoc Dermatol) reported adverse effects in all subjects; 8 treated patients stopped for deranged liver function tests and 1 for anaphylactic shock. Any setting administering IV glutathione must have epinephrine immediately available. For home subcutaneous users, keeping an EpiPen accessible during the first several injections is a reasonable precaution.

A 2025 case report documented acute liver injury with SIRS requiring ICU admission after high-dose IV glutathione. This is a single case, but it reinforces the need for baseline liver function tests and repeat monitoring at six weeks for anyone using 600 mg or more at three times per week.

Rate-dependent reactions are common with IV administration. Rapid IV push frequently produces flushing, nausea, and chest tightness. These are histamine-mediated and resolve completely by slowing the infusion to 15 to 30 minutes. They do not affect efficacy.

Injection site reactions occur with subcutaneous dosing, particularly when users do not rotate sites. Lipohypertrophy (small lumps under the skin) develops with repeated injection at the same location. Rotating at least 2 to 3 cm from the prior site prevents this.

Zinc depletion is a quieter concern. GSH chelates zinc, and chronic high-frequency dosing (three or more times per week for 8 to 12 weeks) may lower serum zinc enough to cause poor wound healing and altered taste. Baseline zinc testing and a recheck at 8 to 12 weeks catches this before symptoms appear.

Sulfite sensitivity reactions have been reported in susceptible individuals. If you have a known sulfite allergy, discuss this with your prescriber before starting injectable GSH.

Pregnancy and breastfeeding are contraindicated due to insufficient safety data for injectable glutathione. Asthma patients should exercise caution, as inhaled GSH has triggered bronchospasm in published reports. Organ transplant recipients on immunosuppressive therapy should avoid GSH given its immune-modulating properties, which could interfere with tacrolimus or cyclosporine.

If you develop chills, fever, and low blood pressure after an injection, stop immediately and seek medical attention. That pattern could indicate endotoxin contamination and requires emergency evaluation.

Common Issues & Solutions

Nausea/flushing/chest tightness during IV: rate-dependent reaction: slow infusion to ≥15–30 min; does not affect efficacy and typically resolves without treatment.

No skin brightening after 10–12 sessions: ~62.5% of users are non-responders per published RCT data; escalating dose past 1,200 mg is unlikely to convert a non-responder and increases adverse event risk.

Skin brightening fading after stopping: expected: published follow-up shows effects fade within 6 months; shift to maintenance dosing (1×/week SubQ) to sustain results rather than stopping completely.

Chills + fever + hypotension after injection: possible endotoxin contamination: STOP immediately, seek medical care. Batch COA and endotoxin test results from the compounding pharmacy can confirm the cause. FDA documented 7 hospitalization cases from contaminated product.

Injection site hardening or lump: rotate injection sites each dose, maintaining ≥2–3 cm from prior site; lipohypertrophy resolves with proper rotation.

Ask AI about this page

Ask AI for a second opinion on Glutathione dosing and side effects

Contraindications

  • Pregnancy or breastfeeding (insufficient safety data for injectable GSH)
  • Known allergy to glutathione or any component of the formulation
  • Active asthma (inhaled GSH may trigger bronchospasm; use injectable forms with caution)
  • Organ transplant recipients on immunosuppressive therapy (GSH may modulate immune response)

Drug Interactions

  • Cisplatin and other platinum-based chemotherapeutics: GSH may reduce nephrotoxicity but could theoretically affect drug efficacy; use only under oncologist guidance
  • Acetaminophen: GSH is depleted during acetaminophen metabolism; high acetaminophen use increases GSH demand
  • Nitroglycerin: concurrent GSH administration may potentiate hypotensive effects
  • Cyclophosphamide: GSH has shown protective effects against urotoxicity in animal models; clinical relevance under investigation
  • Immunosuppressants (tacrolimus, cyclosporine): GSH immune-modulating properties may interfere with immunosuppression
  • IV ozone therapy: concurrent administration defeats the purpose of both agents; ozone generates reactive oxygen species while glutathione acts as an antioxidant to quench them; this creates direct pharmacological antagonism per PMID 40408806 (2025)

Product Quality

Recommended Monitoring

TestWhenTarget
Liver function tests (ALT, AST, ALP, total bilirubin)Baseline before starting high-dose protocols; repeat at 6 weeks if using ≥600 mg × 3×/weekALT/AST within laboratory reference range; values >3× ULN warrant protocol pause
Serum zincBaseline; recheck at 8–12 weeks with high-frequency dosing (≥3×/week chronic use)70–120 mcg/dL
Blood pressure (sphygmomanometer)Before and during IV infusion sessionsNot listed
Liver function tests (ALT, AST, ALP, total bilirubin)

Published IV skin-brightening RCT (Zubair 2016) reported liver enzyme elevations; 2025 case report documented acute liver injury with SIRS (ICU admission) after high-dose IV glutathione.

Serum zinc

Chronic high-dose GSH use may deplete zinc; noted in product literature and community experience. GSH-zinc chelation documented.

Blood pressure (sphygmomanometer)

IV glutathione may potentiate hypotensive effects, particularly when combined with nitroglycerin or in dehydrated patients. 2025 SIRS case presented with BP 50 mmHg. Rate-dependent hemodynamic effects with rapid IV push.

Glutathione Before and After

Week 1

Most users notice increased energy and reduced brain fog within the first few sessions. IV administration shows effects faster than IM or SubQ. No visible skin changes yet.

Weeks 2-4

Improved recovery from exercise, reduced hangover severity, and general well-being reported. Skin may begin to appear slightly brighter or more even-toned at higher doses.

Weeks 4-8

Noticeable skin brightening in many users, especially at doses of 400-600mg 2-3x/week. Nail and hair quality may improve. Liver enzyme panels often show improvement if previously elevated.

Weeks 8-12+

Peak skin-lightening and antioxidant benefits with consistent use. Continued immune and detoxification support. Many users maintain a lower-frequency schedule for upkeep.

What to Expect

Week 1 to 2: Most users notice increased energy and reduced brain fog within the first few sessions. IV administration shows effects within hours; subcutaneous users typically feel changes within days. No visible skin changes at this stage. Injection site soreness and transient nausea (if IV is pushed too quickly) are the most common early side effects. Plasma GSH rises above baseline, and intracellular pools begin replenishing through cysteine delivery.

Weeks 2 to 6: Exercise recovery improves noticeably. Hangover severity drops. Skin may begin appearing slightly brighter or more even at higher doses (400 to 600 mg range). GSH is actively inhibiting tyrosinase in melanocytes at this point, and the eumelanin-to-phaeomelanin shift starts at higher doses. Liver Phase II detoxification enzyme activity rises measurably. Injection site reactions may become more frequent with repeated subcutaneous dosing at the same location, so rotation matters.

Weeks 6 to 12 (12 sessions): This is the response window for skin brightening. The Zubair 2016 RCT found that 37.5% of treatment subjects showed visible skin lightening versus 18.7% on placebo after 12 sessions. Nail and hair quality improvements are commonly reported alongside. Non-responders (roughly 63% of users) should honestly assess whether continuing is worthwhile. Liver enzyme elevations are possible at high IV doses; monitoring ALT and AST is important if running 600 mg or more IV three times per week.

Post-cycle: Skin brightening effects fade within six months of stopping, per published follow-up data. Energy and recovery benefits typically drop off within two to four weeks. The majority of users shift to a maintenance schedule of once per week subcutaneous rather than stopping completely. Plasma GSH returns to individual baseline within days to weeks after discontinuation.

Detailed Timeline: Science vs Community

Week 1–2
Science

Plasma GSH elevated above baseline; intracellular GSH pools begin replenishment via cysteine delivery. No measurable melanin changes at this stage.

Community

Increased energy, reduced brain fog, improved sleep quality most commonly reported. IV users may notice effects within hours of first session; SubQ users within days.

Weeks 2–6
Science

GSH inhibiting tyrosinase activity in melanocytes; eumelanin-to-phaeomelanin shift begins at higher doses. Liver phase II detoxification enzyme activity elevated.

Community

Improved exercise recovery; skin tone may appear slightly brighter or more even. Hangover reduction commonly noted. Reduced post-workout muscle soreness.

Weeks 6–12 (12 sessions)
Science

Zubair 2016: 37.5% of treatment subjects show visible skin lightening vs. 18.7% placebo at 12 sessions. Melanin index reduction measurable in responders. Peak antioxidant enzyme activity.

Community

Noticeable skin brightening and tone evening in responders; nail and hair quality improvements reported. Peak energy and recovery benefits. Non-responders should evaluate whether to continue.

Post-cycle (after stopping)
Science

Skin brightening effects fade within 6 months of discontinuation (Zubair 2016 follow-up). Plasma GSH returns to individual baseline within days to weeks.

Community

Energy/recovery benefits fade 2–4 weeks after stopping. Skin tone gradually returns toward baseline. Majority of users shift to maintenance dosing (1×/week SubQ) rather than stopping completely.

Pharmacokinetics

Half-Life
10min
Bioavailability
IV: 100%; IM/SubQ: near 100% (parenteral bypass of first-pass metabolism); Oral: ~10% due to GI degradation
Tmax
IV: immediate; IM/SubQ: 30-60 minutes (estimated)
Data Confidence
moderate

Source: IV GSH is rapidly oxidized to GSSG with a plasma t½ of ~10 minutes; Aebi et al. 1991 PMID 1907548. Intracellular t½ is longer at 2-3 hours.

Pharmacokinetics: Active Dose Over Time

t½ = ~10 min (plasma); 2-3 hours (intracellular)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
3
Molecular Weight
307.32 Da
Formula
C10H17N3O6S
Type
Small Molecule
Sequence
ECG
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons

Who Should Consider Glutathione

  • Adults seeking antioxidant and detoxification support
  • Individuals with elevated oxidative stress from chronic illness or environmental exposure
  • Those pursuing skin brightening or evening of skin tone
  • Patients undergoing liver-supportive therapy (under medical supervision)
  • Athletes recovering from high-intensity training with elevated ROS production

Related Peptides

What Changed for Glutathione

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 202612 Citations

References

  1. [1]Randomized controlled trial of oral glutathione supplementation on body stores of glutathione (Eur J Nutr, 2015) (opens in a new tab)(n=54)PubMed (opens in a new tab)PubMed
  2. [2]Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function (Eur J Clin Nutr, 2019) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Glutathione as a skin-lightening agent and in melasma: a systematic review (Int J Dermatol 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Glutathione and its antiaging and antimelanogenic effects (Clin Cosmet Investig Dermatol, 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
  5. [5]High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine (Eur J Clin Invest, 1991) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Refrigerate at 2-8°C, protect from light
After Reconstitution
Refrigerate at 2-8°C, use within 4 weeks
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

For efficacy, no. For side effects, yes. Slower infusion over 15-30 minutes reduces the flushing, nausea, and chest tightness that come with rapid administration. No evidence that drip rate changes how well GSH works; only how rough the ride is.

Published data (Zubair et al., 2016) says roughly 12 sessions before visible lightening, only about 37.5% of people respond, and the effects fade within 6 months of stopping. High-dose protocols (1,200+ mg) may show faster onset. Results are not permanent; set your expectations accordingly.

For general antioxidant effects, parenteral bioavailability is similar regardless of route. For skin brightening specifically, IV produces faster peak plasma concentrations which may matter. Home SC works well for maintenance; IV makes more sense for intensive loading. No head-to-head comparison exists.

Two possible causes and one is serious. If you got a rapid IV push, that's likely a rate-dependent histamine response; slow the drip and it resolves. But chills plus fever plus low blood pressure could mean endotoxin contamination from non-pharmaceutical-grade product. The FDA documented 7 endotoxin poisoning cases from contaminated compounded glutathione. If it's the second scenario, stop immediately and get medical attention.

Entirely depends on the compounding pharmacy behind it. PCAB accreditation and proper sterility testing are the main quality markers for 503A compounding pharmacies (prescription required). The FDA's 2019 warning specifically targeted supplement-grade glutathione powder being used for compounding. PCAB accreditation, a COA, and endotoxin test results are the documents that show batch quality.